Hormonal Therapy News and Research

RSS
Hormonal Therapy is treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the body’s natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone. Also called endocrine therapy, hormone therapy, and hormone treatment.
Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Patient navigation may lead to better breast cancer care in high risk and minority women

Patient navigation may lead to better breast cancer care in high risk and minority women

Groundbreaking molecular imaging agent developed to trace advanced prostate cancer

Groundbreaking molecular imaging agent developed to trace advanced prostate cancer

Dieting may decrease chances for metastases in triple negative breast cancers

Dieting may decrease chances for metastases in triple negative breast cancers

Prostate cancer breakthroughs offer new hope for men

Prostate cancer breakthroughs offer new hope for men

Genetic testing may help select women with ER+ breast cancer for extended hormone therapy

Genetic testing may help select women with ER+ breast cancer for extended hormone therapy

Molecular subtyping determines breast cancer patients at high risk of disease recurrence

Molecular subtyping determines breast cancer patients at high risk of disease recurrence

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

ASTRO, SSO guideline focuses on reducing ipsilateral breast tumor recurrence in stages I, II breast cancer

ASTRO, SSO guideline focuses on reducing ipsilateral breast tumor recurrence in stages I, II breast cancer

Patients receiving APBI after breast-conserving surgery show excellent tumor control, breast cosmesis

Patients receiving APBI after breast-conserving surgery show excellent tumor control, breast cosmesis

Z-endoxifen may provide better treatment for women with estrogen positive breast cancer

Z-endoxifen may provide better treatment for women with estrogen positive breast cancer

Early docetaxel drug with ADT increases survival of men with metastatic prostate cancer

Early docetaxel drug with ADT increases survival of men with metastatic prostate cancer

Tasquinimod drug effective for men with metastatic castration-resistant prostate cancer

Tasquinimod drug effective for men with metastatic castration-resistant prostate cancer

Quantitative models predict risk of acute urinary symptoms in prostate cancer patients treated with RT

Quantitative models predict risk of acute urinary symptoms in prostate cancer patients treated with RT

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

Gene sequencing reveals mutations in estrogen receptor

Gene sequencing reveals mutations in estrogen receptor

Data analyses from Brisdelle Phase 3 pivotal trials to be showcased at NAMS' meeting

Data analyses from Brisdelle Phase 3 pivotal trials to be showcased at NAMS' meeting

Long-term hormonal therapy has no additional benefits in men with intermediate-risk prostate cancer

Long-term hormonal therapy has no additional benefits in men with intermediate-risk prostate cancer

FDA grants Breakthrough Therapy designation to Syndax's entinostat for ER+ breast cancer

FDA grants Breakthrough Therapy designation to Syndax's entinostat for ER+ breast cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.